GLP-1 receptor agonists reduce energy intake by up to roughly 40%, according to a 2025 review of the evidence, and they do it through three overlapping pathways: appetite suppression, delayed gastric emptying, and altered nutrient absorption
Even though obesity and depression often occur together, clinical trials typically exclude people with severe depression
Additionally, the peptide appears to interact with multiple growth factor receptors and signaling pathways involved in cellular migration, proliferation, and differentiation, all essential processes for tissue healing
Researchers evaluating intranasal peptide preparations should consult resources like Bachem reference standards and peptide benchmarking to understand how purity certificates and reference standards underpin reproducible results
But concentrations are 7 to 10 times higher in liver cells than anywhere else
The goal is to provide a clear, science-backed understanding of why more is not always better when it comes to GLP-1 therapy